Our writer, who saw an unlikely champion of gay rights fight for his beliefs in an African court, says that there are grounds for optimism in the battle for equality there

It's not just low income countries that have a problem.

An Aids awareness scheme is teaching villagers HIV is an illness, and not caused by witchcraft. By Hazel Southam in Kasarika

In 2000, a year's course of anti-retroviral drugs cost $10,000 and projections caused consternation even in Western countries coping with a few thousand cases of HIV. The idea that treatment might be rolled out to millions in the developing world seemed a pipe dream.

Three decades on from the start of the Aids pandemic, the main global agencies are uncertain whether to be cheerful or gloomy about prospects for the worst disease of modern times .

Patient co-ordinator Chris is one of the longest living survivors of HIV in Britain. He speaks to Patrick Strudwick

I choose not to listen to the cynics, whose philosophical opposition to aid bewilders me

Anti-retrovirals are vital in improving and saving the lives of children with HIV.

A naked doll with long synthetic hair greets the visitor to this inspired exhibition, which explores "the idea of opening up and exposing a living body".

Scientists have added to the list of drugs which could have deadly interactions with grapefruit.

The red ribbon is the universal symbol of awareness and support for those living with HIV. This year marks the 25th anniversary of the National Aids Trust (NAT), the UK's leading charity dedicated to transforming society's response to HIV. In honour of the occasion, a number of NAT's high-profile supporters have created exclusive pieces of red-ribbon art.

Porn producers are threatening to quit filming in Los Angeles after voters approved a measure requiring adult-movie actors to wear condoms during shoots to protect them from sexually transmitted diseases.

Ahead of tomorrow’s High Level Panel meeting in London, a reflection on the critical role of health in and beyond the Millennium Development Goals.

GlaxoSmithKline has beefed up its interest in an HIV drug which analysts regard as a potential multi-billion-dollar-a-year blockbuster.